Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - The Bob Cimis Memorial Lecture - Challenges and Progress Towards the Prevention of Pancreatic Cancer, 10/1/2021 8:00:00 AM - 10/1/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Tamas Gonda, MD
Associate Professor of Medicine
Chief of Endoscopy, Tisch Hospital
Director, Pancreas Disease Program
Division of Gastroenterology & Hepatology
NYU Grossman School of Medicine
About our Presenter
Dr. Tamas Gonda specializes in therapeutic endoscopy with a primary interest in treatment and prevention of pancreatobiliary diseases and advanced endoscopic therapies. His research focus is on early detection and novel treatment of pancreatic cancer. He has lead investigator-initiated and collaborative clinical trials in the treatment of pancreatic cancer and pancreatitis, and prevention and treatment of pancreatic cancer precursors.
Learning Outcome(s)
Following this presentation, participants will be able to identify risk factors for and impact of screening for pancreatic cancer, including the use of imaging and biomarkers.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Tamas Gonda, MD ~ has a research grant from Boston Scientific; he is also a consultant/advisor for Taewoong Endoscopy, Boston Scientific, and Interpace.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Tamas Gonda, MD
Associate Professor of Medicine
Chief of Endoscopy, Tisch Hospital
Director, Pancreas Disease Program
Division of Gastroenterology & Hepatology
NYU Grossman School of Medicine
About our Presenter
Dr. Tamas Gonda specializes in therapeutic endoscopy with a primary interest in treatment and prevention of pancreatobiliary diseases and advanced endoscopic therapies. His research focus is on early detection and novel treatment of pancreatic cancer. He has lead investigator-initiated and collaborative clinical trials in the treatment of pancreatic cancer and pancreatitis, and prevention and treatment of pancreatic cancer precursors.
Learning Outcome(s)
Following this presentation, participants will be able to identify risk factors for and impact of screening for pancreatic cancer, including the use of imaging and biomarkers.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Tamas Gonda, MD ~ has a research grant from Boston Scientific; he is also a consultant/advisor for Taewoong Endoscopy, Boston Scientific, and Interpace.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
